Equillium acquires Bioniz Therapeutics to expand immunomodulatory drug pipeline
Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its pipeline of novel immunomodulatory drug candidates. Bioniz Therapeutics, which is based in Irvine, California, is a clinical-stage biopharma company focused on developing precision cytokine targeted therapies for treating immuno-inflammatory diseases. […]